Prostatype Genomics AB Logo

Prostatype Genomics AB

Provides a genetic test to assess prostate cancer aggressiveness and guide treatment choices.

PROGEN | ST

Overview

Corporate Details

ISIN(s):
SE0022574554 (+2 more)
LEI:
549300JO6MPCGPVHVU91
Country:
Sweden
Address:
Gustav III:s Boulevard 34, 169 73 Solna
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test, Prostatype®. The test is designed to provide a comprehensive assessment of the aggressiveness of diagnosed prostate cancer, particularly for patients with localized disease. It serves as a decision-making tool for clinicians and patients to help determine appropriate treatment strategies. The Prostatype® system uses existing biopsy tissue to analyze the expression of three key genes. This genetic data is combined with standard clinical parameters (PSA, Gleason Score, Tumor Stage) to calculate a proprietary P-score, which quantifies the risk of cancer mortality. By offering a more precise prognosis, the test aims to minimize both over- and under-treatment, thereby improving patient quality of life and saving healthcare resources.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Prostatype Genomics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prostatype Genomics AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Prostatype Genomics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BioSenic SA Logo
Developing ATO and cell therapies for autoimmune diseases and tissue regeneration.
Belgium
BIOS
BIOTECH Logo
Biotech group offering preclinical zebrafish testing & intein tech for human/animal health.
Spain
BST
Biovica International B Logo
Develops blood tests to monitor the efficacy of solid tumor cancer therapies.
Sweden
BIOVIC
Bonus BioGroup Ltd. Logo
Develops cell therapies and tissue products for bone grafts and inflammation repair.
Israel
BONS
BRAIN Biotech AG Logo
Develops custom enzymes and microbes for the food, nutrition, and chemical industries.
Germany
BNN
BriaCell Therapeutics Corp. Logo
Develops off-the-shelf cellular immunotherapies for advanced breast, prostate, and lung cancers.
United States of America
BCTX
BSF ENTERPRISE PLC Logo
Biotech investor developing cell-based tissue solutions for food, materials, and health markets.
United Kingdom
BSFA
BullFrog AI Holdings, Inc. Logo
Leverages causal AI to accelerate drug discovery and identify novel targets for biopharmaceuticals.
United States of America
BFRG
Burning Rock Biotech Ltd Logo
Offers NGS-based diagnostics for precision oncology, from detection to clinical trial support.
United States of America
BNR
Cabaletta Bio, Inc. Logo
Develops engineered T cell therapies for a curative reset in autoimmune diseases.
United States of America
CABA

Talk to a Data Expert

Have a question? We'll get back to you promptly.